| Literature DB >> 34029545 |
Abstract
One of the problems hardly clarified in Coronavirus Disease 2019 (COVID-19) pandemic crisis is to identify factors associated with a lower mortality of COVID-19 between countries to design strategies to cope with future pandemics in society. The study here confronts this problem by developing a global analysis based on more than 160 countries. This paper proposes that Gross Domestic Product (GDP) per capita, healthcare spending and air pollution of nations are critical factors associated with fatality rate of COVID-19. The statistical evidence seems in general to support that countries with a low average COVID-19 fatality rate have high expenditures in health sector >7.5% of GDP, high health expenditures per capita >$2,300 and a lower exposure of population to days exceeding safe levels of particulate matter (PM2.5). Another relevant finding here is that these countries have lower case fatality rates (CFRs) of COVID-19, regardless a higher percentage of population aged more than 65 years. Overall, then, this study finds that an effective and proactive strategy to reduce the negative impact of future pandemics, driven by novel viral agents, has to be based on a planning of enhancement of healthcare sector and of environmental sustainability that can reduce fatality rate of infectious diseases in society.Entities:
Keywords: Air pollution; COVID-19; Case fatality rates; Crisis management; Environmental sustainability; Health expenditures; Health policy; Health systems; Infected people
Year: 2021 PMID: 34029545 PMCID: PMC8139437 DOI: 10.1016/j.envres.2021.111339
Source DB: PubMed Journal: Environ Res ISSN: 0013-9351 Impact factor: 6.498
Descriptive statistics.
| Countries with | Countries with | |||
|---|---|---|---|---|
| Description of variables | M | SD | M | SD |
| - Cases/population, % 2020 | 0.81 | 1.11 | 2.39 | 1.66 |
| - Fatality rate, % 2020 | 2.28 | 1.57 | 1.68 | 0.88 |
| - GDP per capita PPP ($), 2019 | $8,538.85 | $6,035.58$ | $46,634.61 | $20,215.07 |
| - Health expenditure % of GDP, 2017 | 5.97 | 2.12 | 7.59 | 2.77 |
| - General government health expenditure per capita, PPP ($), 2017 | $243.72 | $260.29 | $2,323.90 | $1,373.42 |
| - Population aged 65 years and over as a percentage of population, 2019 | 5.83 | 3.85 | 15.07 | 6.41 |
| - PM2.5 air pollution, population exposed to levels exceeding WHO guideline value (% of total), 2017 | 97.70 | 11.95 | 72.34 | 38.23 |
| - COVID-19 pandemic lockdowns (days), 2020 | 55.26 | 51.22 | 96.71 | 85.79 |
Note: M = arithmetic mean; SD= Standard Deviation.
Fig. 1Fatality of COVID-19, health expenditure and population exposed to high levels of air pollution in countries with GDP per capita higher/lower than $22,794. Note: log values of PM2.5 air pollution are to have comparable numbers in the bar graph.
Independent samples test.
| Levene's Test for equality of variances | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sig. | df | Sig. (2-tailed) | Mean Difference | Std. Error Difference | ||||
| Cases/population %, 2020 | •Equal variances assumed | 17.462 | 0.001 | −7.079 | 153.000 | 0.001 | −0.016 | 0.002 |
| •Equal variances not assumed | −6.431 | 88.151 | 0.001 | −0.016 | 0.002 | |||
| Fatality rate %, | •Equal variances assumed | 7.842 | 0.006 | 2.671 | 154.000 | 0.008 | 0.006 | 0.002 |
| •Equal variances not assumed | 3.057 | 153.670 | 0.003 | 0.006 | 0.002 | |||
| GDP per capita PPP ($), 2019 | •Equal variances assumed | 46.016 | 0.001 | −17.345 | 153.000 | 0.000 | −38095.761 | 2196.380 |
| •Equal variances not assumed | −13.984 | 63.132 | 0.001 | −38095.761 | 2724.193 | |||
| Health expenditure % of GDP, 2017 | •Equal variances assumed | 4.929 | 0.028 | −4.127 | 154.000 | 0.001 | −1.627 | 0.394 |
| •Equal variances not assumed | −3.859 | 96.660 | 0.001 | −1.627 | 0.422 | |||
| General government health expenditure per capita, PPP ($), 2017 | •Equal variances assumed | 163.442 | 0.001 | −14.446 | 152.000 | 0.001 | −2080.181 | 143.998 |
| •Equal variances not assumed | −11.412 | 59.484 | 0.001 | −2080.181 | 182.286 | |||
| Population ages 65 years and over as a percentage of population, 2019 | •Equal variances assumed | 21.540 | 0.001 | −11.266 | 154.000 | 0.001 | −9.244 | 0.821 |
| •Equal variances not assumed | −9.975 | 81.803 | 0.001 | −9.244 | 0.927 | |||
| •Equal variances assumed | 59.944 | 0.001 | 4.311 | 148.000 | 0.001 | 0.518 | 0.120 | |
| •Equal variances not assumed | 3.190 | 52.335 | 0.002 | 0.518 | 0.162 | |||
| •Equal variances assumed | 3.749 | 0.057 | −2.030 | 70.000 | 0.046 | −0.433 | 0.213 | |
| •Equal variances not assumed | −1.999 | 61.106 | 0.050 | −0.433 | 0.217 | |||
Fig. 2Factors associated with a mitigation of case fatality rates of COVID-19 between countries to design general guidelines to constrain pandemic crises of novel viral agents similar to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that is the strain of the novel influenza that causes coronavirus disease 2019 (COVID-19).